reason report
solid outlook weaker near term riski tilt
result beat consensu revenu ep howev
compani revis financi guidanc fell estim
consensu suggest pressur compani revenu
yield per patient product anticip top-
line reduct vs prior guidanc vs consensu attribut
impact result delay start shift
payer mix well dynam relat ultomiri convers
result price headwind compani guidanc reflect
like expens associ acquisit announc
yesterday certainli dilut margin
ep base quarter result better
consensu estim manag commentari revis
guidanc adjust revenu earn forecast
alexion also updat model reflect impact
acquisit expect close
revenu forecast lower adjust slower
growth franchis year margin ep outlook
also reduc base assumpt like dilut
long-term revenu forecast higher
incorpor addit revenu andexxa
chang revenu forecast lower consensu
higher longer term adjust sg
forecast long-term pro forma oper margin expect
slightli higher base chang pro forma
ep estim lower lower
beyond new ep estim lower
recent consensu estim beyond
higher chang estim forecast
account chang peer compani multipl lower
price target modestli reiter
outperform rate alexion stock alexion stock like
view trade sideway sever month pend stabil
revenu outlook potenti clarif revenu trajectori
latest acquisit
averag dcf price-to-earnings
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target rate stock
outperform alexion lead compani develop commerci treatment
complement-medi diseas histor greater alexion revenu come
two rare diseas indic soliri recent approv soliri myasthenia
gravi neuromyel optica nmo on-going launch ultomiri alexion final
diversifi portfolio beyond soliri two core ahu pnh indic
believ alexion increas revenu complement franchis
competit threat soliri overst view given long safeti efficaci
histori soliri well alexion progress develop improv version
ultomiri greater potenc longer half-lif conveni dose beyond
complement kanuma strensiq continu grow steadili still believ two
product could combin contribut expect oper
margin maintain futur find alexion well posit
grow ep doubl digit next five year
alexion report revenu vs con vs us
non-gaap ep vs con us rel strong top-lin result
estim consensu non-gaap ep beat estim
consensu base lower expens higher margin
estim consensu
ultomiri impress sale yoy vs us
vs consensu partial off-set less impress perform soliri
vs us vs consensu manag provid updat
guidanc full-year reflect expect impact lower revenu
non-gaap ep guidanc initi guidanc
lower recent estim
consensu estim new
oper margin guidanc primarili reflect
reduc oper expens guidanc relat clinic trial delay pipelin
updat well reduct sg due reduc commerci activ
expens guidanc decreas previous
consensu estim sg guidanc reduc
 consensu estim
updat guidanc includ potenti impact acquisit would
expect actual oper expens higher reflect acquisit andexxa-
relat cost deal close
soliri sale beat consensu estim total sale soliri
grow qoq yoy driven continu
growth gener myasthenia gravi gmg revenu partial off-set ultomiri
convers dynam alexion reiter neurolog busi remain largest
franchis driven sequenti volum growth reiter expect
expans treat us neurolog patient popul
ultomiri easili beat expect acceler transit soliri alexion
report ultomiri sale higher estim
consensu accord compani paroxysm nocturn hemoglobinuria pnh
convers percentag increas versu versu end decemb
result suggest ultomiri uptak acceler like
result conveni dose schedul overal alexion continu expect
ultomiri reach convers rate
metabol yoy rel flat sequenti basi strensiq
sale estim consensu yoy
volum growth kanuma sale consensu
estim suspect out-performance strensiq driven smaller
impact rel kanuma due abil at-hom administr
ep beat driven stronger expect top line lower expect oper
expens total product revenu beat consensu
estim respect top-lin beat primarili driven stronger
expect perform franchis non-gaap expens
consensu estim non-gaap
sg expens estim consensu
non-gaap consensu
estim alexion paid tax rate averag dilut
share count million quarter non-gaap basi report non-gaap
ep consensu estim
impact reflect updat guidanc earn call
manag provid updat guidanc suggest moder top-lin
oper expens expect compani guid total product sale
versu prior earn call guidanc midpoint
repres rel declin midpoint substanti lower
recent consensu estim due three primari
factor includ volum impact anticip slower patient start due patient
distanc price headwind due acceler ultomiri convers shift public
payer due rise unemploy also appear impair treatment
persist particularli hard-hit intern market spain itali
reduct complianc would expect rel larger impact result compar
new start compani indic continu see strong complianc us
expect complianc treatment-delay relat impact like
preferenti impact indic gmg oppos pnh sinc patient
less like becom symptomat treatment interv extend
increas profit temporarili compani increas oper margin
guidanc repres increas midpoint rel
initi guidanc driven expens reduct due clinic trial
delay remov affibodi mileston reduct like partial off-set
increas clinic trial spend expand access program
invest virtual promot activ ep compani guid pro forma ep
midpoint initi guidanc
lower recent consensu estim compani
indic anticip suppli disrupt due
includ impact acquisit updat guidanc guidanc
particularli expens pro forma ep like advers affect
recent announc acquisit portola close year
timelin key pipelin program larg intact slight delay due
portfolio adjust manag provid updat across compani
pipelin extens alexion commentari acquisit call yesterday
alexion highlight critic care franchis potenti area growth particularli given
nearli atyp hemolyt urem syndrom ahu grow number
neuromyel optica spectrum disord nmosd patient initi therapi
hospit set seem eager develop scope product offer
acquisit plan pursu potenti indic andexxa
includ urgent surgeri set alexion also initi random phase trial
ultomiri sever pneumonia ard assess overal
surviv day recent acquir achillion portfolio alexion plan begin phase
studi assess danicopan pnh patient extravascular hemolysi
guid toward top-lin readout phase studi quarter
compani indic new clinic trial like experi delay due covid-
obviou timelin chang relat plan launch
studi al-amyloidosi trial expect start previous
phase studi danicopan pnh push back
previous timelin fcrn program also push back due
combin decis transit iv sq formul waiha well
delay phase sq studi healthi volunt result alexion
plan initi phase trial waiha previous expect gmg
previous expect addit alexion indic plan pursu
dose schedul bispecif mini-bodi via auto-injector pre-fil
syring decid discontinu develop clinic develop program
ultomiri ppm base retrospect clinic biomark analysi
price target base simpl averag three
approach believ reason basi valu stock today
approach simpl price earn multipl compar large-cap biopharma
ratio discount cash flow dcf use rel multipl similar growth compani
ep appli ep estim alexion give fair valu
stock use expect ep compound-annual-growth-rate alexion
period current averag ratio larg molecul large-cap biotech
give ep multipl discount
multipl compress alexion appli ep estim give
fair valu final dcf use termin growth rate post give
current valu averag three valuat methodolog pt
risk view outlook valuat alexion includ major chang price
reimburs coverag label soliri compani main product today
risk includ commerci develop disappoint recent launch product
strensiq kanuma well develop disappoint addit indic
soliri successor complement inhibitor product asset obtain
recent acquisit final brand gener competitor product soliri come
market captur greater share caus greater market price disrupt
current expect futur outlook valuat would undermin opportun
better perform valu expect includ stronger initi adopt
recent launch new product forecast success develop
commerci new indic soliri beyond neuromyel optica
myasthenia gravi novel rare diseas medicin time horizon forecast
sale non-gaap
share count period dilut
guidanc
late stage pipelin program includ
late stage pipelin program exclud
brand
type event
event trial detail
date known
up/down
expect
bridg trial pnh indic
file japan regulatori approv
anticip close acquisit
initi phase
initi phase
initi phase portion phase studi investig add-
current standard-of-car therapi
initi phase trial japan pend regulatori feedback
initi phase trial add-on therapi soliri pnh
initi poc trial combin
initi phase studi waiha
initi phase studi gmg
svb leerink llc equiti research compani file
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
analysi stock price svb leerink target alexion
multipl ep svb leerink estimate earn
current averag larg cap biopharma multipl ep
svb leerink adjust ep estim
capit
number period
impli target price
method leerink intrins valu base dcf current product net
current svb leerink dcf marketed/l stage program
current estim valu asset
method project forward earn multipl ep base ep
compound-annual-growth-rate larg cap biotech ratio
averag slow growth larg cap biotech co
impli ep multipl discount vs full growth-adj multipl
averag method
svb leerink llc research compani file factset
